Undaunted Bio is a seed-stage startup using a clinically informed, AI-driven, network-medicine approach to repurposing existing drugs for neuropathic pain. Our goal is to develop an Oral Thin Film reformulation of UDB412, a promising candidate for the treatment of Trigeminal Neuralgia, a debilitating facial pain condition with a significant unmet medical need. We then intend to broaden the indications for UDB412 to other neuropathic pain conditions, such as post-herpetic neuralgia, and diabetic neuropathic pain. We are on track to commence human trials by 2025 and aim for approval by 2028, using the FDA’s 505(b)(2) regulatory pathway.